Syndax Pharmaceuticals financials
$18.24+2.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0.00 | $0.00 | $139.7M | $1.5M | $1.5M | $1.5M | $2.1M | $1.2M |
| Gross profit | $165.4M | $22.9M | $0.00 | $0.00 | $139.7M | $1.5M | $1.5M | $1.5M | $2.1M | $1.2M |
| Gross margin | 96.0% | 96.5% | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M | -$71.4M | -$57.5M | -$75.9M | -$62.0M | -$43.8M |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M | -$77.1M | -$56.0M | -$74.0M | -$60.8M | -$47.1M |
| Net margin | −165.6% | −1346.1% | — | — | 17.8% | −5080.0% | −3694.6% | −4875.5% | −2884.3% | −3858.2% |
| Diluted EPS | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 | $-1.87 | $-1.84 | $-2.92 | $-2.90 | $-3.22 |
| EBITDA | -$273.1M | -$339.7M | -$229.9M | -$151.7M | $26.3M | -$71.3M | -$57.4M | -$75.8M | -$61.9M | -$43.7M |
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M | -$71.3M | -$50.6M | -$68.5M | -$47.4M | -$35.2M |
| Free cash flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M | $29.0M | -$71.3M | — | -$68.7M | -$47.5M | -$35.4M |
| Diluted shares | 86.6M | 85.6M | 70.4M | 60.8M | 53.6M | 41.3M | 30.5M | 25.4M | 21.0M | 14.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $222.0M | $115.2M |
| Short-term investments | $259.1M | $418.8M | $275.3M | $401.4M | $218.0M | $177.8M |
| Total debt | $345.0M | $345.3M | $22.0K | $18.0K | $19.9M | $20.1M |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M | $300.6M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M | $48.4M |
| Shareholders' equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M | $252.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology